| Recent clinical studies (DAPA-HF, EMPEROR-Reduced and EMPEROR-Preserved, SOLOIST-WHF trial) and meta-analysis have demonstrated that sodium–glucose cotransporter-2 inhibitors (SGLT2i) are among the first antidiabetic drugs capable of reducing cardiovascular risks related to HF and improving the prognosis of patients with and without diabetes (Diabetes Therapy)
In this article, we briefly review the different mechanisms of action that may explain the renal beneficial effects of SGLT2i and disclose the results of the key renal outcome trials and the subsequent update of related clinical guidelines (Diabetes Therapy)
This supplement summarizes all the evidence of this therapeutic change and reviews the role of these drugs from prevention to management of patients who have already developed complications, such as patients with HF and chronic kidney disease (Diabetes Therapy)
These studies are the first to demonstrate that LD individuals in LMICs have a unique metabolic profile, suggesting that this is a distinct entity that warrants further investigation (Diabetes Care)
Normal birth weight is associated with achieving significantly lower mean CGM glucose concentration across the 24-h day and higher CGM time in range from before the end of the first trimester, emphasizing the need for a shift in clinical management, with increased focus on using weekly CGM glucose targets for optimizing maternal glycemia from early pregnancy (Diabetes Care)
In patients with T1DM and IAH, hypoglycaemic parameters were associated with better cardiovascular autonomic function and lower prevalence of CAN. This suggests that autonomic neuropathy does not seem to further deteriorate hypoglycaemic risk in patients with IAH (Diabetes Research and Clinical Practice)
Dapagliflozin can reduce arterial stiffness in people with T2DM, which is associated with an increased susceptibility to atherosclerosis regardless of age. Dapagliflozin is also associated with a significant decrease in BP and a favourable lipid profile, producing a decrease in the most atherogenic LDL fractions and an increase in HDL-C (Diabetes Therapy)
These data are consistent with a role for fluoxetine in regulating glucose homeostasis through direct effects at beta-cells. Fluoxetine thus demonstrates promise as a preferential antidepressant for patients with concomitant occurrence of depression and diabetes (Diabetes, Obesity and Metabolism)
| 